New England Journal Of Medicine Publishes Results From A RELISTOR Phase 3 Clinical Study

Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ) , and Progenics Pharmaceuticals, Inc. ( Nasdaq: PGNX ) announced publication of results from a pivotal phase 3 trial of RELISTOR ( TM ) ( methylnaltrexone bromide ) subcutaneous injection in the May 29, 2008 issue of the New England Journal of Medicine. RELISTOR is a newly approved therapy for treatment of opioid-induced constipation ( OIC ) in patients with advanced illness who are receiving palliative care, when response to laxative therapy hasn't been sufficient.

The clinical study showed that significantly more OIC patients with advanced illness experienced bowel movements ( laxation ) within four hours of receiving their first dose of subcutaneous RELISTOR than patients receiving placebo, without use of a rescue laxative ( 48 percent vs. 15 percent; P <0. 001 ) . The study also demonstrated that RELISTOR did not impair ability of opioids to provide pain relief, and drug was generally well tolerated.

" Effectively managing pain is critical for patients with advanced illness, " says Jay Thomas, M. D. , Ph. D. , a lead author of study and Clinical Medical Director of The San Diego Hospice and the Institute for Palliative Medicine. " However, side effects associated with many pain medications can represent a significant barrier to providing good pain management for those patients. The data published in NEJM are particularly exciting because not only do they demonstrate that RELISTOR has potential to relieve OIC effectively, but that it does so without interfering with much-needed pain relief. '

Each year, more than 1. 5 million Americans receive palliative care due to an advanced illness, such as incurable cancer, end-stage heart and lung disease, or AIDS. A considerable number of these patients are prescribed opioids to manage their pain, and experts say that constipation occurs in practically all of them. However, for many, laxatives don't provide sufficient relief. RELISTOR, administered via subcutaneous injection, is a peripherally acting mu-opioid receptor antagonist that counteracts constipating effects of opioid pain medications in the gastrointestinal tract without impacting opioid-mediated analgesic effects on the central nervous system.

Study Design and Results

The double-blind, randomized, placebo-controlled phase 3 trial examined efficacy and safety of subcutaneous RELISTOR in relieving OIC in patients with an advanced illness. Co-primary end points were proportion of patients with a rescue-free bowel movement within four hours of first dose, and proportion of patients with rescue-free bowel movements occurring within four hours of at least two of first four doses, both compared to placebo. Patients who completed two-week, placebo-controlled trial were eligible to enter a subsequent three-month, open-label extension study. Patients in extension study received RELISTOR as needed, not more frequently than once daily, for up to three months.

In double-blind phase of the study, 48 percent of patients experienced a bowel movement within four hours of receiving the first dose of RELISTOR ( 0. 15 mg/kg ) , more than three times the rate seen in patients treated with placebo ( 15 percent; P <0. 001 ) . Half of the RELISTOR patients who responded within 4 hours did so within 30 minutes. Additionally, more patients receiving RELISTOR ( 52 percent ) experienced a bowel movement within four hours of receiving at least two of first four doses than those receiving placebo ( 8 percent ) ( P <0. 001 ) . The response rates remained consistent throughout the extension study. Overall safety data from studies showed that RELISTOR was generally well tolerated. The most frequently reported adverse events were abdominal pain and flatulence.

Full study results from this first published analysis of a phase 3 subcutaneous RELISTOR trial can be found in current issue of New England Journal of Medicine ( http: //content. nejm. org ) .

About RELISTOR

RELISTOR was recently approved in the United States for treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR beyond four months hasn't been studied. RELISTOR has also been approved in Canada and received a positive opinion from Committee for Medicinal Products for Human Use ( CHMP ) , scientific committee of the European Medicines Agency ( EMEA ) . EMEA regulatory action is pending.

Important Safety Information for RELISTOR

-- RELISTOR is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

-- If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their physician.

-- Use of RELISTOR hasn't been studied in patients with peritoneal catheters.

-- The most common adverse reactions with RELISTOR in clinical trials were abdominal pain, flatulence, and nausea.

RELISTOR Prescribing Information is available at http: //www. relistor. com

About the Companies

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products. Wyeth is one of world's largest research-driven pharmaceutical and health care products companies. It's a leader in discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

WYETH DISCLOSURE NOTICE: The statements in this press release that aren't historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, there can be no assurance that subcutaneous form of RELISTOR will be commercially successful in United States and Canada or that RELISTOR will be successfully developed and commercialized in other formulations or indications and/or in other countries. Other risks and uncertainties that could cause actual results to differ materially from those expressed or implied by forward-looking statements include, without limitation, the inherent uncertainty of timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; importance of strong performance from our principal products and our anticipated new product introductions; highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under caption " Item 1A, RISK FACTORS " in our Annual Report on Form 10-K for year ended December 31, 2007, which was filed with Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Progenics Pharmaceuticals, Inc. , of Tarrytown, NY, is a biopharmaceutical company focusing on development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward gastroenterology as well as treatment of HIV infection and cancer. The Company, in collaboration with Wyeth, is developing RELISTOR for treatment of opioid-induced side effects, including constipation ( oral and subcutaneous formulations ) and postoperative ileus ( intravenous formulation ) . In the area of HIV infection, Company is developing the viral-entry inhibitor PRO 140, a humanized monoclonal antibody targeting HIV entry co-receptor CCR5, which has completed phase 1b clinical studies with positive results. In area of prostate cancer, the Company is developing a human monoclonal antibody drug conjugate -- a selectively targeted cytotoxic antibody directed against prostate-specific membrane antigen ( PSMA ) , a protein found on surface of prostate cancer cells. Progenics is also developing vaccines designed to stimulate an immune response to PSMA.

PROGENICS DISCLOSURE NOTICE: The information contained in this document is current as of May 28, 2008. This press release contains forward-looking statements. Any statements contained herein that are not statements of historical fact may be forward-looking statements. When Company uses words " anticipates, " " plans, " " expects " and similar expressions, it's identifying forward-looking statements. Such forward-looking statements involve risks and uncertainties which may cause Company's actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such factors include, among others, uncertainties associated with product development, risk that clinical trials won't commence or proceed as planned, the risks and uncertainties associated with dependence upon the actions of our corporate, academic and other collaborators and of government regulatory agencies, the risk that our licenses to intellectual property may be terminated because of our failure to have satisfied performance milestones, the risk that products that appear promising in early clinical trials don't demonstrate efficacy in larger-scale clinical trials, risk that we may not be able to manufacture commercial quantities of our products, uncertainty of future profitability and other factors set forth more fully in the Company's Annual Report on Form 10-K for fiscal year ended December 31, 2007, and other reports filed with Securities and Exchange Commission, to which investors are referred for further information. In particular, Company can't assure we that any of its programs will result in a commercial product. Progenics doesn't have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. Thus, it should not be assumed that Company's silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.

Additional information on Progenics is available at http: //www. progenics. com.

Additional information on Wyeth is available at http: //www. wyeth. com.

Additional information regarding RELISTOR is available at http: //www. relistor. com.

Wyeth Pharmaceuticals http: //www. wyeth. com

Safe methos to cancel pregnancy

Ramipril information.

uses of Ramipril Ramipril belongs to a group of medications called ACE inhibitors. It's used to treat high blood pressure ( hypertension ) . It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.

Ramipril is also used to prevent heart problems ( such as heart attacks ) and/or strokes in certain high risk patients, and with other drugs ( e. g. , " water pills " /diuretics, digoxin ) to treat congestive heart failure.

how to use of Ramipril Take Ramipril by mouth, usually once or twice a day; or as directed by your doctor. You may take Ramipril with or without food. Use Ramipril regularly in order to get the most benefit from it. Remember to use it at the same time ( s ) each day.

Swallow the capsule form whole. If you can't swallow capsule, open it and sprinkle contents on a small amount ( 4 oz. ) of applesauce or mix with apple juice or water. Swallow or drink the entire mixture.

Don't take potassium supplements or salt substitutes containing potassium without talking to your doctor or pharmacist first. This medicine can raise your potassium levels, which rarely can cause serious side effects such as muscle weakness or very slow heartbeats. Tell your doctor immediately if these effects occur.

The dosage is based on your medical condition and response to therapy. For treatment of high blood pressure, it may take several weeks before full benefit of Ramipril occurs or several weeks to months when used for congestive heart failure.

It's important to continue taking Ramipril even if we feel well. Most people with high blood pressure do not feel sick.

other used of Ramipril This section contains uses of Ramipril that aren't listed in approved professional labeling for the drug but that may be prescribed by your health care professional. Use Ramipril for a condition that's listed in this section only if it has been so prescribed by your health care professional.

Ramipril may also be used to help protect kidneys from damage due to diabetes.

side effects of Ramipril We may experience dizziness, light-headedness, fatigue, nausea, vomiting, diarrhea, dry cough or blurred vision as your body adjusts to medication. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Remember that your doctor has prescribed Ramipril because he or she has judged that benefit to we is greater than risk of side effects. Many people using Ramipril don't have serious side effects.

Tell your doctor immediately if any of these unlikely but serious side effects occur:

Tell your doctor immediately if any of these highly unlikely but very serious side effects occur:

Ramipril may rarely cause serious ( possibly fatal ) liver problems. If you notice any of following highly unlikely but very serious side effects, seek immediate medical attention:

A serious allergic reaction to Ramipril is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction include:

This is not a complete list of possible side effects. If we notice other effects not listed above, contact your doctor or pharmacist.

precautions of Ramipril Before taking Ramipril, tell your doctor or pharmacist if we are allergic to it; or to other ACE inhibitors ( e. g. , benazepril, captopril ) ; or if you have any other allergies ( including an allergic reaction after exposure to certain membranes used for blood filtering ) .

Ramipril should not be used if we have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if we have:

Before using Ramipril, tell your doctor or pharmacist your medical history, especially of:

Ramipril may make we dizzy; use caution engaging in activities requiring alertness such as driving or using machinery. Limit alcoholic beverages.

To minimize dizziness and light-headedness due to lowering of your blood pressure, get up slowly when rising from a seated or lying position. Serious loss of body fluids can also lower your blood pressure and worsen dizziness. Drink adequate fluids to prevent from becoming dehydrated. If we are on restricted fluid intake, consult your doctor for further instructions. Be careful not to become too overheated during exercise which can lead to excessive sweating. Consult your doctor if we experience severe vomiting or diarrhea.

Before having surgery, tell your doctor or dentist that we are taking Ramipril.

Caution is advised when using Ramipril in the elderly because they may be more sensitive to its effects, especially dizziness.

Ramipril isn't recommended for use during pregnancy due to risk for harm to an unborn baby. Consult your doctor for more details. ( See also Warning section. )

It's not known if Ramipril passes into breast milk. Breast-feeding is not recommended due to potential harm to the nursing infant. Consult your doctor before breast-feeding.

interactions of Ramipril Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring we for them. Don't start, stop, or change dosage of any medicine before checking with them first.

Before using Ramipril, tell your doctor or pharmacist of all prescription and nonprescription products we may use, especially of:

A very serious reaction may occur while use Ramipril if we are getting injections for bee/wasp sting allergy ( desensitization ) and are also taking Ramipril. Make sure all your doctors know which medicines we are using.

Check labels on all your medicines ( e. g. , cough-and-cold products, diet aids ) because they may contain ingredients that could increase your heart rate or blood pressure. Ask your pharmacist about safe use of those products.

This document doesn't contain all possible interactions. Therefore, before using Ramipril, tell your doctor or pharmacist of all the products we use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

overdose of Ramipril If overdose of Ramipril is suspected, contact your local poison control center or emergency room immediately. US residents can call US national poison hotline at 1-800-222-1222. Canadian residents should call their local poison control center directly. Symptoms of overdose may include: unusually fast or slow heartbeat, severe dizziness, fainting.

notes of Ramipril Don't share Ramipril with others. Lifestyle changes such as stress reduction programs, exercise and dietary changes may increase effectiveness of this medicine. Talk to your doctor or pharmacist about lifestyle changes that might benefit you.

Laboratory and/or medical tests ( e. g. , kidney function, potassium blood level ) should be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

Check your blood pressure regularly while taking this medication, especially when you first start Ramipril or when your dose is changed. Learn how to monitor your own blood pressure at home, and share results with your doctor.

missed dose of Ramipril If you miss a dose Ramipril, use it as soon as we remember. If it is near time of next dose, skip missed dose and resume your usual dosing schedule. Do not double dose of Ramipril to catch up.

storage of Ramipril Store Ramipril at room temperature between 59-86 degrees F ( 15-30 degrees C ) away from light and moisture. Do not store Ramipril in bathroom. If we have opened capsule form and mixed it with food or liquid, this mixture can be kept at room temperature for 24 hours or refrigerated for 48 hours. Keep all medicines away from children and pets.

Properly discard Ramipril when it's expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

warning of Ramipril Ramipril can cause serious ( possibly fatal ) harm to an unborn baby if used during pregnancy. Therefore, it's important to prevent pregnancy while taking Ramipril. Consult your doctor for more details and to discuss the use of reliable forms of birth control while taking this medication. If we are planning pregnancy, become pregnant, or think we may be pregnant, contact your doctor immediately.

FDA approved Ramipril

Device Identifies Fatty Deposits in Coronary Arteries. A new medical device allows doctors to see the plaque buildup on the wall of coronary arteries. Many heart attacks occur when a fatty coronary plaque ruptures, forming dangerous blood clots.

Beware of Bug Bites and Stings. Ticks, mosquitoes, and bees--here are tips for preventing and treating bug bites and stings.

Combating Antibiotic Resistance. Misuse and overuse of antibiotics have contributed to antibiotic resistance, a phenomenon that reduces or eliminates the effectiveness of antibiotics.

Celebrating the Successes of the Orphan Drug Act. The Orphan Drug Act was signed into law 25 years ago. Find out what it is, what it's done, and what it means for the future of millions of people with rare diseases and conditions

Drug Approved for Irritable Bowel Syndrome with Constipation. FDA has approved Amitza (lubiprostone) for the treatment of irritable bowel syndrome with constipation in adult women aged 18 and over

Embracing Chaos. Our youngest, 9-year-old Oskar, was the one who first figured out that the name of the whale was Chaos.

In Wolf Trap's 'Vienna Woods,' a Tour of German Song. At a time when there is so much focus on creative programming as a Holy Grail in classical music, it's bewildering that Steven Blier does not get more respect.

At Guitar Fest, Virtuosity From Sensual to Poetic. One of the most exciting gems of the summer music season is the Alexandria Guitar Festival -- an intensive week of concerts and master classes held at the George Washington Masonic Memorial every July. Classical guitarists from around the country flock to it -- there's a stack o..

Tappening, Spotlighting The Art of Footwork. Tap-dancing is a peculiarly obsessive art, honed in loneliness, its devotees driven to find the tiniest ways to produce big sounds, or to deliver a rat-a-tat clarity whose source no eye could follow. Because it's so blasted hard to do, it's one of the few popular dance styles you're unlikely to s..

A Diverse Cast of One-Person Shows. Do you like your theater literal and low-key, or avant-garde and abstract? It seems the Capital Fringe Festival has something for every taste.

At This Gathering, Weather Buffs Are on Cloud Nine. Here, huddled in the basement of a hotel in Crystal City, is a group of guys who hate the dull, sweltering dog days of summer even more than most. They cool themselves down with a good old game of Remember When.

Liberal Bloggers Brace for Victory. AUSTIN, July 20 -- "Yep, the way it's looking, we might actually win this thing..".

Times Columnist Uncovers His Darkest Story. David Carr's latest subject is a pathetic human being, a thug, a manipulative jerk who uses people and puts his own kids in danger.

License, Registration And Weight, Please. Consider the driver's license. That unimpeachable document you show to enter government buildings, get on a plane or go anywhere sensitive in this post-9/11 world. It's the cornerstone of our security these days, used to weed out the dangerous terrorist from the benign traveler. The legal from the..

Keeping a food diary helps dieters lose weight. Dieters who track their food consumption in a diary - along with exercising and eating right - can double their weight loss, according to a study published last week in the American Journal of Preventive..